CR20220278A - Derivados de 3-(5-metoxi-1-oxoisoindolin-2-il)piperidin-2,6-diona y usos de los mismos - Google Patents
Derivados de 3-(5-metoxi-1-oxoisoindolin-2-il)piperidin-2,6-diona y usos de los mismosInfo
- Publication number
- CR20220278A CR20220278A CR20220278A CR20220278A CR20220278A CR 20220278 A CR20220278 A CR 20220278A CR 20220278 A CR20220278 A CR 20220278A CR 20220278 A CR20220278 A CR 20220278A CR 20220278 A CR20220278 A CR 20220278A
- Authority
- CR
- Costa Rica
- Prior art keywords
- oxoisoindolin
- piperidine
- methoxy
- hemoglobinopathies
- beta
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente divulgación se relaciona con composiciones farmacéuticas y compuestos de fórmula (I’) y con su uso para reducir los niveles de expresión de los Motivos de Dedos de Zinc Ampliamente Interespaciados (WIZ), o para inducir la expresión de la hemoglobina fetal (HbF), y para el tratamiento de trastornos sanguíneos hereditarios (<em>por ejemplo,</em> hemoglobinopatías, <em>por ejemplo,</em> beta-hemoglobinopatías), tales como la enfermedad de células falciformes y la beta-talasemia.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962950048P | 2019-12-18 | 2019-12-18 | |
| PCT/IB2020/062070 WO2021124172A1 (en) | 2019-12-18 | 2020-12-16 | 3-(5-methoxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20220278A true CR20220278A (es) | 2022-07-01 |
Family
ID=73856242
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20220278A CR20220278A (es) | 2019-12-18 | 2020-12-16 | Derivados de 3-(5-metoxi-1-oxoisoindolin-2-il)piperidin-2,6-diona y usos de los mismos |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US11566022B2 (es) |
| EP (1) | EP4076650B1 (es) |
| JP (1) | JP2023506642A (es) |
| KR (1) | KR20220114065A (es) |
| CN (1) | CN114828959B (es) |
| AR (1) | AR120773A1 (es) |
| AU (1) | AU2020410514A1 (es) |
| BR (1) | BR112022011796A2 (es) |
| CA (1) | CA3164832A1 (es) |
| CO (1) | CO2022008243A2 (es) |
| CR (1) | CR20220278A (es) |
| DO (1) | DOP2022000121A (es) |
| EC (1) | ECSP22055267A (es) |
| ES (1) | ES2980575T3 (es) |
| IL (1) | IL293530A (es) |
| JO (1) | JOP20220152A1 (es) |
| MX (1) | MX2022007351A (es) |
| PE (1) | PE20230159A1 (es) |
| TW (1) | TW202130631A (es) |
| UY (1) | UY38986A (es) |
| WO (1) | WO2021124172A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230285570A1 (en) * | 2020-08-07 | 2023-09-14 | Cornell University | Therapeutically useful cure-pro molecules for e3 ligase mediated degradation of proteins, and methods of making and using them |
| UY39671A (es) | 2021-03-15 | 2022-10-31 | Novartis Ag | Derivados de pirazolopiridina y sus usos. |
| CN117062811A (zh) | 2021-06-03 | 2023-11-14 | 诺华股份有限公司 | 3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其医疗用途 |
| JP2024528143A (ja) * | 2021-07-30 | 2024-07-26 | ヒノバ ファーマシューティカルズ インコーポレイテッド | 二官能性キメラ複素環式化合物及びアンドロゲン受容体分解剤としての使用 |
| CN118556048A (zh) * | 2022-12-27 | 2024-08-27 | 标新生物医药科技(上海)有限公司 | 基于硫/氧取代戊二酰亚胺基异吲哚啉酮骨架的化合物及其应用 |
| CN115959976A (zh) * | 2022-12-30 | 2023-04-14 | 安徽诺全药业有限公司 | 一种甲氧基取代双环戊烷衍生物的制备方法 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW589189B (en) | 1997-08-04 | 2004-06-01 | Scras | Kit containing at least one double-stranded RNA combined with at least one anti-viral agent for therapeutic use in the treatment of a viral disease, notably of viral hepatitis |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| AUPP249298A0 (en) | 1998-03-20 | 1998-04-23 | Ag-Gene Australia Limited | Synthetic genes and genetic constructs comprising same I |
| GB9827152D0 (en) | 1998-07-03 | 1999-02-03 | Devgen Nv | Characterisation of gene function using double stranded rna inhibition |
| AU776150B2 (en) | 1999-01-28 | 2004-08-26 | Medical College Of Georgia Research Institute, Inc. | Composition and method for (in vivo) and (in vitro) attenuation of gene expression using double stranded RNA |
| DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
| WO2001029058A1 (en) | 1999-10-15 | 2001-04-26 | University Of Massachusetts | Rna interference pathway genes as tools for targeted genetic interference |
| GB9927444D0 (en) | 1999-11-19 | 2000-01-19 | Cancer Res Campaign Tech | Inhibiting gene expression |
| EP1354038A2 (en) | 2000-12-28 | 2003-10-22 | J & J Research Pty Ltd | Double-stranded rna-mediated gene suppression |
| CA2514733A1 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| SI3202461T1 (sl) * | 2010-02-11 | 2019-05-31 | Celgene Corporation | Derivati arilmetoksi izoindolina in sestavki, ki jih vsebujejo in metode uporabe le teh |
| WO2012068512A1 (en) | 2010-11-18 | 2012-05-24 | Deuteria Pharmaceuticals Llc | 3-deutero-pomalidomide |
| WO2012079022A1 (en) | 2010-12-10 | 2012-06-14 | Concert Pharmaceuticals, Inc. | Substituted dioxopiperidinyl phthalimide derivatives |
| US9133161B2 (en) | 2012-07-27 | 2015-09-15 | Celgene Corporation | Processes for preparing isoindoline-1,3-dione compounds |
| JP2018523823A (ja) | 2015-08-04 | 2018-08-23 | セルジーン コーポレイション | 慢性リンパ球性白血病の治療方法及び免疫調節療法に対する臨床的感度の予測因子としてのバイオマーカーの利用 |
| CN109071552B (zh) | 2016-04-22 | 2022-06-03 | 达纳－法伯癌症研究所公司 | 细胞周期蛋白依赖性激酶4/6(cdk4/6)通过cdk4/6抑制剂与e3连接酶配体的缀合的降解及使用方法 |
| KR102173463B1 (ko) | 2016-10-11 | 2020-11-04 | 아비나스 오퍼레이션스, 인코포레이티드 | 안드로겐 수용체의 표적 분해용 화합물 및 방법 |
| CA3042260C (en) | 2016-11-01 | 2023-10-03 | Arvinas, Inc. | Tau-protein targeting protacs and associated methods of use |
| BR112019011200B1 (pt) | 2016-12-01 | 2021-12-28 | Arvinas Operations, Inc | Derivados de tetrahidronaftaleno e tetrahidroisoquinolina como degradadores do receptor de estrogênio |
| JP2020504741A (ja) | 2016-12-23 | 2020-02-13 | アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． | Ｒａｆ（急速進行性線維肉腫）ポリペプチドの標的分解のための化合物および方法 |
| US10806737B2 (en) | 2016-12-23 | 2020-10-20 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of fetal liver kinase polypeptides |
| EP3559002A4 (en) | 2016-12-23 | 2021-02-17 | Arvinas Operations, Inc. | CHEMERICAL MOLECULES TARGETING EGFR PROTEOLYSIS AND RELATED METHODS OF USE |
| US11191741B2 (en) | 2016-12-24 | 2021-12-07 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide |
| WO2018140809A1 (en) | 2017-01-26 | 2018-08-02 | Arvinas, Inc. | Modulators of estrogen receptor proteolysis and associated methods of use |
| EP3697436A1 (en) | 2017-10-18 | 2020-08-26 | Novartis AG | Compositions and methods for selective protein degradation |
| WO2019079701A1 (en) | 2017-10-20 | 2019-04-25 | Dana-Farber Cancer Institute, Inc. | HETEROBIFUNCTIONAL COMPOUNDS HAVING IMPROVED SPECIFICITY FOR BRD4 BROMODOMAINE |
| US11065231B2 (en) | 2017-11-17 | 2021-07-20 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides |
| IL315310A (en) | 2017-12-26 | 2024-10-01 | Kymera Therapeutics Inc | IRAK joints and used in them |
| WO2019177902A1 (en) | 2018-03-10 | 2019-09-19 | Yale University | Modulators of btk proteolysis and methods of use |
| WO2019191112A1 (en) * | 2018-03-26 | 2019-10-03 | C4 Therapeutics, Inc. | Cereblon binders for the degradation of ikaros |
| AU2019249231B2 (en) | 2018-04-04 | 2022-04-21 | Arvinas Operations, Inc. | Modulators of proteolysis and associated methods of use |
| EP3814380A4 (en) | 2018-06-29 | 2022-06-15 | Dana Farber Cancer Institute, Inc. | BI-SPECIFIC DEGRADING AGENTS |
| US11530219B2 (en) | 2018-06-29 | 2022-12-20 | Dana-Farber Cancer Institute, Inc. | Ligands to cereblon (CRBN) |
| JP7328263B2 (ja) | 2018-06-29 | 2023-08-16 | ダナ－ファーバー キャンサー インスティテュート，インコーポレイテッド | 免疫調節化合物 |
| US12030892B2 (en) | 2018-06-29 | 2024-07-09 | Dana-Farber Cancer Institute, Inc. | CRBN modulators |
| EP3890736A4 (en) | 2018-12-03 | 2022-08-10 | Dana Farber Cancer Institute, Inc. | HELIOS SMALL MOLECULE DEGRADERS AND METHOD OF USE |
-
2020
- 2020-12-16 CR CR20220278A patent/CR20220278A/es unknown
- 2020-12-16 WO PCT/IB2020/062070 patent/WO2021124172A1/en active Application Filing
- 2020-12-16 TW TW109144481A patent/TW202130631A/zh unknown
- 2020-12-16 JO JOP/2022/0152A patent/JOP20220152A1/ar unknown
- 2020-12-16 US US17/124,127 patent/US11566022B2/en active Active
- 2020-12-16 KR KR1020227024287A patent/KR20220114065A/ko active Search and Examination
- 2020-12-16 UY UY0001038986A patent/UY38986A/es unknown
- 2020-12-16 BR BR112022011796A patent/BR112022011796A2/pt not_active Application Discontinuation
- 2020-12-16 EP EP20828350.7A patent/EP4076650B1/en active Active
- 2020-12-16 CA CA3164832A patent/CA3164832A1/en active Pending
- 2020-12-16 CN CN202080087049.9A patent/CN114828959B/zh active Active
- 2020-12-16 IL IL293530A patent/IL293530A/en unknown
- 2020-12-16 PE PE2022001098A patent/PE20230159A1/es unknown
- 2020-12-16 AU AU2020410514A patent/AU2020410514A1/en not_active Abandoned
- 2020-12-16 ES ES20828350T patent/ES2980575T3/es active Active
- 2020-12-16 JP JP2022537250A patent/JP2023506642A/ja active Pending
- 2020-12-16 MX MX2022007351A patent/MX2022007351A/es unknown
- 2020-12-16 AR ARP200103501A patent/AR120773A1/es unknown
-
2022
- 2022-06-13 CO CONC2022/0008243A patent/CO2022008243A2/es unknown
- 2022-06-14 DO DO2022000121A patent/DOP2022000121A/es unknown
- 2022-07-14 EC ECSENADI202255267A patent/ECSP22055267A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2980575T3 (es) | 2024-10-02 |
| AR120773A1 (es) | 2022-03-16 |
| DOP2022000121A (es) | 2022-08-15 |
| JP2023506642A (ja) | 2023-02-17 |
| BR112022011796A2 (pt) | 2022-08-30 |
| MX2022007351A (es) | 2022-07-19 |
| US20220402904A1 (en) | 2022-12-22 |
| CN114828959A (zh) | 2022-07-29 |
| PE20230159A1 (es) | 2023-02-01 |
| TW202130631A (zh) | 2021-08-16 |
| EP4076650A1 (en) | 2022-10-26 |
| ECSP22055267A (es) | 2022-08-31 |
| CA3164832A1 (en) | 2021-06-24 |
| IL293530A (en) | 2022-08-01 |
| KR20220114065A (ko) | 2022-08-17 |
| CN114828959B (zh) | 2024-04-02 |
| UY38986A (es) | 2021-07-30 |
| EP4076650B1 (en) | 2024-02-28 |
| WO2021124172A1 (en) | 2021-06-24 |
| AU2020410514A1 (en) | 2022-06-30 |
| CO2022008243A2 (es) | 2022-07-08 |
| JOP20220152A1 (ar) | 2023-01-30 |
| US11566022B2 (en) | 2023-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022007351A (es) | Derivados de 3-(5-metoxi-1-oxoisoindolin-2-il)piperidin-2,6-diona y usos de los mismos. | |
| CY1113766T1 (el) | Παραγωγα ινδολιδονης για την θεραπεια ή προληψη ινωτικων ασθενειων | |
| MX2011010859A (es) | Peptidos utiles en el tratamiento y/o cuidado de la piel y/o cabello y su uso en composiciones cosmeticas o farmaceuticas. | |
| MX2019013561A (es) | Compuestos de pirrolopiridina-anilina para el tratamiento de trastornos dermicos. | |
| TW200612903A (en) | Use of trisubstituted benzopyranones | |
| TW200731975A (en) | Novel combinations of medicaments for the treatment of respiratory diseases | |
| BR112012028321A2 (pt) | "compostos análogos de desazadesferrotiocina e desazadesferrotiocina poliéter como agentes de quelação de metal, composição farmacêutica e usos dos ditos compostos" | |
| ATE451922T1 (de) | Verwendung von thiazolidinon-derivaten zur behandlung von festen tumoren | |
| BR112014028813A2 (pt) | 5-amino[1,4]tiazinas como inibidores bace1 | |
| CY1116234T1 (el) | Υποκατεστημενα 2-οξυ-κινολινο-3-καρβοξαμιδια σαν διαμορφωτες kcnq2/3 | |
| WO2018005801A3 (en) | Novel non-systemic tgr5 agonists | |
| NZ328874A (en) | Heterocyclic biaryl compounds and their use in pharmaceutical compositions for treatment of dermatological, rheumatic, respiratory, cardiovascular and ophthalmological disorders | |
| CY1110644T1 (el) | 5,6,7-τριυδροξυεπτανοϊκο οξυ και τα αναλογα για την θεραπεια οφθαλμικων ασθενειων που σχετιζονται με υπερεκφυτικες και αγγειογενεις αντιδρασεις | |
| IN2011KN05169A (es) | ||
| MX2013002208A (es) | Derivados de sulfonilpiperazina que interactuan con la proteina reguladora de glucocinasa para el tratamiento de diabetes. | |
| CO2024000013A2 (es) | Derivados de 3–(1–oxoisoindolin–2–il)piperidina–2,6–diona y sus usos médicos | |
| RU2008138358A (ru) | Композиция с фиксированной дозой фитата и цинка | |
| DE59909607D1 (de) | Tan-1057 derivate | |
| NO20053876L (no) | Karbonylaminosubstituerte acylfenylurederivater, fremgangsmate for deres fremstilling samt anvendelse derav | |
| ZA202307290B (en) | Pyrazolopyridine derivatives and uses thereof | |
| WO2006087147A3 (en) | Derivatives of aryl (or heteroaryl) azolylcarbinols for the treatment of fibromyalgia | |
| UA94596C2 (ru) | N-сульфамоил-n'-бензопиранпиперидины, предназначенные для применения в медицине | |
| SG11201806628UA (en) | New bi-aromatic propynyl compounds, pharmaceutical and cosmetic compositions containing them and uses thereof | |
| WO2021011500A3 (en) | Use of a benzoate containing composition to treat neurodegenerative disorders | |
| SA521430969B1 (ar) | تركيبات صيدلانية من توليفة ثابتة الجرعة وفورية الإطلاق، وطرقها، واستخداماتها |